Related Experiment Videos
Soluble IL-6 receptor release by PMNs and PBMC in patients with oral cavity cancer
E Jabłońska1, L Piotrowski, Z Grabowska
1Department of Immunopathology, Medical Academy of Białystok.
Abstract:
It is known that the main source of cytokine and soluble cytokine receptors are mononuclear cells in the peripheral blood. Data including the release of soluble mediators by polymorphonuclear cells (PMNs) are controversial. In these examinations using an in vitro model, we studied the ability of spontaneous and LPS-stimulated PMNs to the release of soluble IL-6 receptor (IL-6sR) in oral cavity cancer patients. Obtained results were compared to the release of IL-6sR by a peripheral blood mononuclear cells (PBMC) and the serum levels. The concentrations of IL-6sR in the culture supernatants of cells and in the serum were tested by ELISA. The culture supernatants of spontaneous and LPS-stimulated PMNs derived from oral cavity cancer patients contained an insignificant lower concentrations of IL-6sR than those from healthy subjects. The concentrations of IL-6sR released by PBMC were higher than those released by PMNs in both control and patient groups. There was correlation between the amounts of IL-6sR in the culture supernatants of spontaneous PMNs and PBMC. The altered ability of PMNs and PBMC to the release of IL-6sR may influence the immune response of host to tumor mediated by IL-6.
Insights
Polymorphonuclear cells (PMNs) and peripheral blood mononuclear cells (PBMCs) from oral cancer patients show altered release of soluble IL-6 receptor (IL-6sR). This may impact the immune response to IL-6 mediated tumor immunity.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Peripheral blood mononuclear cells (PBMCs) are known cytokine producers.
- The role of polymorphonuclear cells (PMNs) in releasing soluble mediators like soluble IL-6 receptor (IL-6sR) is debated.
- IL-6 signaling is crucial in cancer immunity.
Purpose of the Study:
- To investigate the release of IL-6sR by PMNs in oral cavity cancer patients.
- To compare IL-6sR release from PMNs and PBMCs in cancer patients versus healthy controls.
- To assess the correlation between IL-6sR levels in cells and serum.
Main Methods:
- In vitro study using oral cavity cancer patient samples.
- Analysis of spontaneous and lipopolysaccharide (LPS)-stimulated PMNs.
- Enzyme-linked immunosorbent assay (ELISA) to quantify IL-6sR concentrations in cell culture supernatants and serum.
- Comparison with peripheral blood mononuclear cells (PBMCs) and healthy subjects.
Main Results:
- PMNs from oral cancer patients released lower concentrations of IL-6sR compared to healthy subjects.
- PBMCs released significantly higher concentrations of IL-6sR than PMNs in both groups.
- A correlation was observed between IL-6sR levels in spontaneous PMN and PBMC cultures.
- Serum IL-6sR levels were also analyzed.
Conclusions:
- Oral cancer alters the IL-6sR release capacity of both PMNs and PBMCs.
- These alterations in IL-6sR release may modulate the host's IL-6-mediated immune response against tumors.
- Further research is needed to elucidate the precise mechanisms and clinical implications.